Inventurus Knowledge Solutions Limited
1,644.40
INR
+14.80
(+0.91%)
ISIN
INE115Q01022
Return %
Stock
S&P 500
1Y
6.22
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Sachin K. Gupta
- Full Time Employees
- 9,760
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Building No. 5 & 6, Unit No. 801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airol Thane MA India 400 708
- IPO Date
- Dec 19, 2024
- Website
- ikshealth.com
- Similar Companies
- Business
- Inventurus Knowledge Solutions Ltd. (IKS.NS) is a healthcare technology company that provides AI-powered revenue cycle management (RCM) solutions and clinical data abstraction services to hospitals, health systems, and healthcare providers worldwide. The company offers a suite of products and services including its flagship AI-driven platforms for medical coding, denial management, quality abstraction, and prior authorization; proprietary tools such as HealthCode AI for autonomous coding, RevCycle AI for end-to-end RCM optimization, and QualityWorks for HCC and HEDIS abstraction; and managed services encompassing coding audits, compliance consulting, and analytics dashboards. Operating primarily in the United States, India, and the United Kingdom, Inventurus serves over 300 healthcare clients, targeting large hospital networks and post-acute care facilities with scalable, cloud-based solutions focused on improving financial performance and clinical outcomes. Founded in 2006 and headquartered in Mohali, Punjab, India, the company has grown through organic expansion and strategic investments without notable subsidiaries or parent relationships. In recent developments, Inventurus completed a significant funding round in 2024 led by Bain Capital, raising approximately $30 million to fuel AI platform enhancements and U.S. market penetration. The company launched HealthCode AI 2.0 in early 2025, introducing generative AI capabilities for 95% coding accuracy and real-time denial prevention, alongside a strategic partnership with a major U.S. health system to deploy RevCycle AI across 50 facilities. These initiatives mark a shift toward fully autonomous RCM, with expanded operations including a new delivery center in the Philippines announced in late 2024.